• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Epidemiological aspects of relapses in leprosy.

作者信息

Pönnighaus J M, Sterne J A

机构信息

Universitäts-Hautklinik, Homburg/Saar, Germany.

出版信息

Indian J Lepr. 1995 Jan-Mar;67(1):35-44.

PMID:7622929
Abstract

Life table methods in which the cumulative probability of relapse in successive periods is calculated are preferable to the presentation of overall relapse rates. Their use facilitates the comparison of relapse rates and trends from different studies independent of duration of follow-up. Results from various studies including data from Malawi indicate that, (1) unlike after dapsone monotherapy, the cumulative probability of relapse in multibacillary patients is near to zero after WHO/MDT if strict definitions of relapse are used and, (2) the cumulative probability of relapse may approach 5% in paucibacillary patients 10 years after completion of WHO/MDT. On the whole, the epidemiological relevance of relapses is insignificant and future treatment regimens should be evaluated concerning their efficacy in preventing disabilities rather than relapses.

摘要

相似文献

1
Epidemiological aspects of relapses in leprosy.
Indian J Lepr. 1995 Jan-Mar;67(1):35-44.
2
Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.18剂世界卫生组织/多药联合化疗方案对多菌型麻风病是否足够;马拉维一项试验的结果
Int J Lepr Other Mycobact Dis. 1995 Mar;63(1):1-7.
3
Risk of relapse in leprosy. The Leprosy Unit, WHO.麻风病的复发风险。世界卫生组织麻风病防治单位
Indian J Lepr. 1995 Jan-Mar;67(1):13-26.
4
Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.中国麻风病复发风险研究:多药联合治疗后的复发情况
Int J Lepr Other Mycobact Dis. 1999 Dec;67(4):379-87.
5
Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy.中国麻风病复发风险的研究:单用氨苯砜治疗后的复发情况
Int J Lepr Other Mycobact Dis. 1999 Dec;67(4):371-8.
6
Rate and time distribution of relapses in multibacillary leprosy.
Int J Lepr Other Mycobact Dis. 1989 Sep;57(3):599-606.
7
Risk of relapse in leprosy after fixed-duration multidrug therapy.固定疗程多药联合治疗后麻风病的复发风险
Int J Lepr Other Mycobact Dis. 1997 Jun;65(2):238-45.
8
Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
Int J Lepr Other Mycobact Dis. 1994 Sep;62(3):353-8.
9
Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.世界卫生组织两年期联合化疗(MDT)对多菌型(MB)麻风病患者的长期疗效。
Int J Lepr Other Mycobact Dis. 2003 Dec;71(4):308-19. doi: 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2.
10
Relapses in multibacillary leprosy patients after multidrug therapy.多菌型麻风患者在接受多药联合治疗后的复发情况。
Lepr Rev. 2008 Sep;79(3):320-4.